ALNYLAM PHARMACEUTICALS, INC. Quarterly Common Stock, Shares Authorized from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Alnylam Pharmaceuticals, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q2 2010 to Q3 2024.
  • Alnylam Pharmaceuticals, Inc. Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 250M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 250M 0 0% Sep 30, 2024 10-Q 2024-10-31
Q2 2024 250M 0 0% Jun 30, 2024 10-Q 2024-08-01
Q1 2024 250M 0 0% Mar 31, 2024 10-Q 2024-05-02
Q4 2023 250M 0 0% Dec 31, 2023 10-Q 2024-10-31
Q3 2023 250M 0 0% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 250M 0 0% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 250M 0 0% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 250M 0 0% Dec 31, 2022 10-K 2024-02-15
Q3 2022 250M 0 0% Sep 30, 2022 10-Q 2022-10-27
Q2 2022 250M 0 0% Jun 30, 2022 10-Q 2022-07-28
Q1 2022 250M 0 0% Mar 31, 2022 10-Q 2022-04-28
Q4 2021 250M 0 0% Dec 31, 2021 10-K 2023-02-23
Q3 2021 250M 0 0% Sep 30, 2021 10-Q 2021-10-28
Q2 2021 250M 0 0% Jun 30, 2021 10-Q 2021-08-03
Q1 2021 250M 0 0% Mar 31, 2021 10-Q 2021-04-29
Q4 2020 250M 0 0% Dec 31, 2020 10-K 2022-02-10
Q3 2020 250M 0 0% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 250M 0 0% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 250M +125M +100% Mar 31, 2020 10-Q 2020-05-06
Q4 2019 250M +125M +100% Dec 31, 2019 10-K 2021-02-11
Q3 2019 250M +125M +100% Sep 30, 2019 10-Q 2019-10-31
Q2 2019 250M +125M +100% Jun 30, 2019 10-Q 2019-08-06
Q1 2019 125M 0 0% Mar 31, 2019 10-Q 2019-05-02
Q4 2018 125M 0 0% Dec 31, 2018 10-K 2020-02-13
Q3 2018 125M 0 0% Sep 30, 2018 10-Q 2018-11-07
Q2 2018 125M 0 0% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 125M 0 0% Mar 31, 2018 10-Q 2018-05-04
Q4 2017 125M 0 0% Dec 31, 2017 10-K 2019-02-14
Q3 2017 125M 0 0% Sep 30, 2017 10-Q 2017-11-07
Q2 2017 125M 0 0% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 125M 0 0% Mar 31, 2017 10-Q 2017-05-05
Q4 2016 125M 0 0% Dec 31, 2016 10-K 2018-02-15
Q3 2016 125M 0 0% Sep 30, 2016 10-Q 2016-11-03
Q2 2016 125M 0 0% Jun 30, 2016 10-Q 2016-08-04
Q1 2016 125M 0 0% Mar 31, 2016 10-Q 2016-05-04
Q4 2015 125M 0 0% Dec 31, 2015 10-K 2017-02-15
Q3 2015 125M 0 0% Sep 30, 2015 10-Q 2015-11-09
Q2 2015 125M 0 0% Jun 30, 2015 10-Q 2015-08-07
Q1 2015 125M 0 0% Mar 31, 2015 10-Q 2015-05-08
Q4 2014 125M 0 0% Dec 31, 2014 10-K 2016-02-12
Q3 2014 125M 0 0% Sep 30, 2014 10-Q 2014-11-06
Q2 2014 125M 0 0% Jun 30, 2014 10-Q 2014-08-08
Q1 2014 125M 0 0% Mar 31, 2014 10-Q 2014-05-09
Q4 2013 125M 0 0% Dec 31, 2013 10-K 2015-02-13
Q3 2013 125M 0 0% Sep 30, 2013 10-Q 2013-11-07
Q2 2013 125M 0 0% Jun 30, 2013 10-Q 2013-08-09
Q1 2013 125M 0 0% Mar 31, 2013 10-Q 2013-05-07
Q4 2012 125M 0 0% Dec 31, 2012 10-K 2014-02-20
Q3 2012 125M 0 0% Sep 30, 2012 10-Q 2012-11-05
Q2 2012 125M 0 0% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 125M 0 0% Mar 31, 2012 10-Q 2012-05-03
Q4 2011 125M 0 0% Dec 31, 2011 10-K 2013-02-19
Q3 2011 125M 0 0% Sep 30, 2011 10-Q 2011-11-03
Q2 2011 125M 0 0% Jun 30, 2011 10-Q 2011-08-03
Q1 2011 125M Mar 31, 2011 10-Q 2011-05-05
Q4 2010 125M Dec 31, 2010 10-K 2012-02-13
Q3 2010 125M Sep 30, 2010 10-Q 2010-11-04
Q2 2010 125M Jun 30, 2010 10-Q 2010-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.